Methods of associating genetic variants with a clinical outcome in patients suffering from age-related macular degeneration treated with anti-VEGF

Patent metadata

Field	Value
Publication number	US-12571027-B2
Application number	US-202418829672-A
Country	US
Kind code	B2
Filing date	Sep 10, 2024
Priority date	May 25, 2018
Publication date	Mar 10, 2026
Grant date	Mar 10, 2026

Abstract

Disclosed herein are methods and compositions for associating a genetic variant with intraretinal fluid. Also disclosed herein are methods and compositions for associating a genetic variant with visual acuity, anatomic outcomes or treatment frequency.

First claim

What is claimed is:

1 . A method of treating a macular degeneration patient with a vascular endothelial growth factor (VEGF) inhibitor, comprising:
administering the VEGF inhibitor under a modified dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient about every 8 weeks, wherein the modified dosing frequency is administering about 2 mg of the VEGF inhibitor to the patient about every 4 to 6 weeks when the patient does not have one or more of the genetic variants rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095; or administering the VEGF inhibitor under a modified dosing frequency after about one year of administering about 2 mg of the VEGF inhibitor to the patient from about every 8 weeks, wherein the modified dosing frequency is administering about 2 mg of the VEGF inhibitor to the patient about every 9 to 12 weeks when the patient has one or more of the genetic variants rs2056688, rs5962084, rs5962087, rs5915722, and rs5962095.

2 . The method of claim 1 , wherein the genetic variant is rs5962087.

3 . The method of claim 1 , wherein the genetic variant is rs5962084.

4 . The method of claim 1 , wherein the genetic variant is rs2056688.

5 . The method of claim 1 , wherein the genetic variant is rs5915722.

6 . The method of claim 1 , wherein the genetic variant is rs5962095.

7 . The method of claim 1 , wherein the VEGF inhibitor is ranibizumab or aflibercept.

8 . The method of claim 1 , wherein the VEGF inhibitor is aflibercept.

9 . The method of claim 4 , wherein the VEGF inhibitor is aflibercept.

10 . The method of claim 1 , wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 9 weeks.

11 . The method of claim 1 , wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 10 weeks.

12 . The method of claim 1 , wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 11 weeks.

13 . The method of claim 1 , wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient having one or more of the genetic variants is modified from about every 8 weeks to about every 12 weeks.

14 . The method of claim 1 , wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 4 weeks.

15 . The method of claim 1 , wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 5 weeks.

16 . The method of claim 1 , wherein the dosing frequency of administering about 2mg of the VEGF inhibitor to the patient not having one or more of the genetic variants is modified from about every 8 weeks to about every 6 weeks.

Assignees

• Regeneron Pharma

Inventors

• Perlee Lorah
• Hamon Sara
• Paulding Charles

Classifications

• G16B30/00

  ICT specially adapted for sequence analysis involving nucleotides or amino acids · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title

• G16H50/20

  for computer-aided diagnosis, e.g. based on medical expert systems · CPC title

• A61K39/001135

  Vascular endothelial growth factor [VEGF] · CPC title

• C12Q1/6809

  Methods for determination or identification of nucleic acids involving differential detection · CPC title